No abstract available.

Recently the clinical estimation of gestational age has been of increasing concern particularly in premature babies because of its great aid in treament and expectation of future health. The clinical distinction between small-for-dates infants and premature babies offers great difficulty, but can be made readily if the gestational age is known. The author has investigated the clinical estimation of gestational age in 100 premature infants who were born at the Seoul National University Hospital, the Eul Ji Hospital and the So Wha Hospital from March to August in 1977, in order to evaluate the correlation between the gestationl age calculated from LMP and the clinically estimated gestaionl age using two charts designed by Brazie and Lubchenco, which were based on 16 physical criteria and 20 neurologic criteria with the following results. 1) The sex and age distribution of the 100 premature infants showed predominance in male and in the 34th336th weeks of gestional age. 2) The numbers of babies whose weight was appropriate, small and large for gestational age were 89, 9 and 2 respectively according to University of Colorado Medical Center Example, while they were 91, 4 and 5 according to the chart based on Rha's report in 1976 in Korea. 3) The correlation percentages between the gestational age determined by each of the 16 physical criteria and those calculated from LMP were as following; vernix (88%), skin and nail plates(88%), recoil-leg(75%), skin thickness appearance(73%), sole creases(68%), genitalia, testes and scrotum(67.5%) and so forth. 4) The correlation percentages between the gestational ages determined by each of the 20 neurologic criteria and those calculated from LMP were as following, pupillary reflex(94%), grasp reflex(90%), vertical positions(87%), head lag (83%), glabellar tap(81%), body extensors(80%), horizontal positions(80%), rooting reflex(80%), and so forth. 5) The correlation coefficiency between the clinically estimated gestational age using the above described two charts and that calculated from LMP was 0.98. And the regression formula for the latter (X) against the former (Y) was Y=0.786X+7.753. With the above results, the author could conclude that clinical estimation of the gestational age with the two charts of Brazie and Lubchenco was highly correlated and it deserves to be recommended for clinical purpose.
Age Distribution ; Colorado ; Genitalia ; Gestational Age* ; Hand Strength ; Head ; Humans ; Infant ; Infant, Newborn ; Infant, Premature* ; Korea ; Male ; Seoul ; Skin ; Testis

No abstract available.
Tonsillectomy*

No abstract available.
Lithotripsy* ; Salivary Gland Calculi* ; Salivary Glands* ; Shock*

No abstract available.

No abstract available.
Ceruloplasmin* ; Cholesterol, HDL* ; Copper* ; Humans ; Infant, Newborn* ; Iron* ; Zinc*

PURPOSE: This study was conducted to investigate whether the use of HA-CMC solution in thyroid surgery influences drainage amount and hospital stay. METHODS: Between November 2012 and December 12, 147 patients with thyroid cancer who underwent total thyroidectomy with central compartment neck dissection were analyzed retrospectively. The patients were divided into four groups; those with or without HA-CMC solution application and high or low output drainage. RESULTS: There were no differences in hospital stay and mean total drainage between the with and without HA-CMC solution application groups (P=0.230, P=0.732). The mean hospital stay was 2.2±0.4 days for the low output of drainage group and 3.1±0.6 days for the high output drainage group (P<0.001). There was no significant difference in the use of HA-CMC solution (41.1% vs. 56.8%, P=0.070). CONCLUSION: The use of HA-CMC solution in thyroid cancer surgery might not increase drainage amount and make hospital stay longer.
Drainage* ; Humans ; Length of Stay ; Neck Dissection ; Retrospective Studies ; Thyroid Gland* ; Thyroid Neoplasms* ; Thyroidectomy

Leiomyosarcoma is an uncommon tumor which arises from various sites including uterus, stomach, retroperitoneum, superficial soft tissues, bladder, kidney, and lung. Primary hepatic leiomyosarcoma is a very rare tumor and fewer than 70 cases of primary hepatic leiomyosarcoma have been reported since the first publication in Japan. And there was only one case report of cutaneous metastasis from hepatic leiomyosarcoma. We recently experienced a case of primary hepatic leiomyosarcoma presenting as subcutaneous palpable mass. Herein we report this case with a review of literatures.
Head and Neck Neoplasms/*secondary ; Humans ; Leiomyosarcoma/diagnosis/*secondary ; Liver Neoplasms/diagnosis/*pathology ; Male ; Middle Aged ; *Scalp ; Skin Neoplasms/*secondary

The intensive use of chemotherapeutic agents for the treatment of cancer has resulted in the cure or improved survival of many patients. But unfortunately, many cancers including human hepatocellular carcinoma (HCC) don't respond to chemotherapy. One of the major mechanisms for the drug resistance in the HCC is an elevated MDR1 RNA expression which makes cells become multidrug resistant. To overcome the multidrug resistance (MDR) phenotype, a high dose of verapamil is required both clinically and experimentally. Accordingly we have examined the MDR modulating effects with combinations of tamoxifen, cyclosporin A, and verapamil in vitro with the physiologically achievable concentrations of each agent, i.e., 2.0 microM/L for tamoxifen, 1.6 microM/L for cyclosporin A, and 2.5 microM/L for verapamil respectively in HCC lines. As expected, verapamil alone with the physiologically achievable concentration at which we tested didn't enhance the doxorubicin cytotoxicity in the HCC lines. Furthermore, any verapamil combination with cyclosporin A or tamoxifen was not effective in overcoming the doxorubicin resistance in the high MDR1 expressor (Hep-G2) line. However tamoxifen reduced the IC50 of doxorubicin by a factor of 1.9 in the low MDR1 expressor (SK-Hep1) and 1.1 in the high MDR1 expressor line (p< 10(-5) respectively). Of interest, combinations of tamoxifen and cyclosporin A showed a significant reduction in the IC50 of doxorubicin in both HCC lines. The IC50 of doxorubicin was reduced by a factor of 3.9 and 1.3, i.e., from 0.023943 micrograms/ml to 0.006157 micrograms/ml (p< 10(-5)) in the SK-Hep1 cell line, and 0.068819 micrograms/ml to 0.052442 micrograms/ml (p< 10(-5)) in Hep-G2 respectively when tamoxifen and cyclosporin A were administered together. Both the estrogen and progesterone receptors in the SK-Hep1 and Hep-G2 lines were less than 0.01 fmol/mg of cytosol protein, respectively. It is therefore suggested that the reversal of doxorubicin resistance is unrelated to their anti-estrogenic activity in the HCC lines. Three modulator combinations of tamoxifen, cyclosporin A, and verapamil were not more effective than the combination of tamoxifen and cyclosporin A on the sensitivity to doxorubicin. MDR modulators of tamoxifen, cyclosporin A, and verapamil didn't reduce the IC50 of cisplatin to the clinically achievable concentration range in HCC lines. In summary, the combination of tamoxifen and cyclosporin A at the concentrations normally seen after clinical administration of these modulators showed significant synergism on the sensitivity to doxorubicin in both low and high MDR1 expressor HCC lines. These data indicate the need for in vivo trials.
Antineoplastic Agents/*pharmacology ; Carcinoma, Hepatocellular/*physiopathology ; Cyclosporine/*pharmacology ; Drug Resistance ; Human ; Liver Neoplasms/*physiopathology ; Support, Non-U.S. Gov't ; Tamoxifen/*pharmacology ; Tumor Cells, Cultured/drug effects ; Verapamil/*pharmacology

No abstract available.
Picibanil* ; Pleural Effusion, Malignant*